Antibodies for all: The case for genome-wide affinity reagents.
For more than 30 years, the production of research antibodies has been dominated by hybridoma technologies, while modern recombinant technologies have lagged behind. Here I discuss why this situation must change if we are to generate reliable, comprehensive reagent sets on a genome-wide scale, and I describe how a cultural shift in the research community could revolutionize and modernize the affinity reagent field. In turn, such a revolution would pay huge dividends by closing the gap between basic research and therapeutic development, thus enabling the development of myriad new therapies for unmet medical needs.
Banting and Best Department of Medical Research, University of Toronto, The Donnelly Centre, 160 College Street, Toronto, Ontario, Canada. sachdev.sidhu@utoronto.ca
Sachdev S
SS
Sidhu
D000818:Animals; D000906:Antibodies / Q000737:chemistry*; D016678:Genome; D015894:Genome, Human; D055106:Genome-Wide Association Study; D006801:Humans; D007202:Indicators and Reagents / Q000737:chemistry*; D019151:Peptide Library; D011485:Protein Binding; D025941:Protein Interaction Mapping / Q000379:methods*; D017434:Protein Structure, Tertiary; D049490:Systems Biology / Q000379:methods; D018909:src Homology Domains
D000906:Antibodies; D007202:Indicators and Reagents; D019151:Peptide Library